• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Renal denervation: Medtronic launches afib trial

Renal denervation: Medtronic launches afib trial

April 30, 2015 By Brad Perriello

Renal denervation: Medtronic launches afib trial

Medtronic (NYSE:MDT) today said it’s launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation.

The Fridley, Minn.-based medical device giant said the 245-patient Symplicity AF trial is a prospective, randomized, multi-center feasibility study. It’s designed to compare RDN and pulmonary vein isolation using a cardiac ablation catheter with PVI alone, Medtronic said.

Symplicity AF is for patients with paroxysmal or persistent afib in patients with both afib and hypertension, using Medtronic’s Arctic Front Advance cryoablation system and Symplicity Spyral RDN system. Seventy patients will be randomized to either PVI alone or the combination treatment; all will be implanted with the Reveal Linq cardiac monitor.

The primary safety endpoint is a composite of PVI -and RDN-related events, Medtronic said; the primary efficacy endpoint is freedom from AF lasting 30 seconds or longer, or requiring intervention, for a minimum of 6 months. Symplicity AF is also designed to collect feasibility outcomes data on the Arctic Front Advance device in persistent AF, the company said.

"Hypertension is one of the most prevalent risk factors for developing AF, but we’ve seen that it is also potentially the most modifiable risk factor for halting the progression of the disease," principal investigator Dr. Larry Chinitz of the NYU Langone Medical Center said in prepared remarks. "As we continue to look for ways to prevent AF recurrence and improve outcomes for patients with AF, this trial may reveal a potential new treatment path for patients."

"The Symplicity AF study, investigating 3 of Medtronic’s notable technologies, is a groundbreaking effort and an excellent example of our commitment to driving clinical benefit through innovation," added executive vice president Michael Coyle. "Only Medtronic has the breadth and depth of cardiac-related technology to investigate new treatment and disease management strategies in this unique manner for some of the most difficult-to-treat conditions, such as AF."

Filed Under: News Well Tagged With: Cardiac Rhythm Management, Clinical Trials, Renal

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy